Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats
- 61 Downloads
The present study was carried out to investigate the pharmacokinetic and pharmacodynamic drug interaction of irbesartan with glipizide after single and multi dose treatment in normal and hypertensive rat models to evaluate the safety and effectiveness of the combination.
The study was conducted on normal and 10% fructose solution induced hypertensive rats. Irbesartan and glipizide were administered orally for 7 days and on 8th day blood samples were collected for 12 h at regular time intervals from irbesartan alone and in combination with glipizide treated groups. The blood samples were analyzed for various pharmacokinetic and pharmacodynamic parameters.
Irbesartan caused marked reduction in blood pressure in hypertensive rats. The combination of irbesartan and glipizide in hypertensive rats produce significant change in blood pressure (pharmacodynamic) and also significance in pharmacokinetic parameters of irbesartan with glipizide in single dose and multiple doses.
The results of present study demonstrated that the synergistic activity of irbesartan with glipizide was observed.
KeywordsIrbesartan Glipizide Pharmacokinetic Pharmacodynamic Antihypertensive activity
We would like to thank management of Vaagdevi College of Pharmacy, Warangal for providing all facilities. Authors were also thankful to A.I.C.T.E for providing fund for lab under MODROBS scheme (8024/RIFD/MOD-354(PVT)/policy-III/2011-2012).
Compliance with Ethical Standards
This study was not funded.
Conflict of Interest
Authors declares there is no conflict of interest.
Prior the investigation, all the animal experiments were reviewed and approved by the Institutional Animal Ethical Committee (IEAC), Vaagdevi pharmacy college, Warangal, India (1047/ac/07/CPCSEA, Dated 24-04-2007). All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 1.Asif H, Parminder SB. A review of pharmacological and pharmaceutical profile of irbesartan. Int Res J. 2011;2(6):276–86.Google Scholar
- 4.David AW. Drug metabolism. In: Thomas LL, David AW, editors. Foye’s principles of medicinal chemistry, vol 6. Philadelphia: Lippincott Williams and Wilkins; 2008. p. 253–326.Google Scholar
- 5.Gopala TE, Krishna Murthy C, Mayuren A. Pharmacokinetics of gliclazide alone and in combination with irbesartan in rabbits. Res J Pharm Tech. 2008;1(4):418–21.Google Scholar
- 6.Goyal RK, Joshi SS, Shah TS. Effects of chronic treatment with Nitrendipine in streptozotocin-induced diabetic rats. Ind J Pharm Sci. 1996;58(3):100–5.Google Scholar
- 12.Rang HP, Dale MM, Ritter JM, Moore PK. Text book of pharmacology, vol 5. New York: Churchill Livingstone; 2005. p. 666–7.Google Scholar
- 13.Ravinder P, Vanishree S, Sujatha S, Kishore Kumar K. Effect of carvedilol on pharmacokinetic and pharmacodynamic of glipizide. Int J Pharm Pharm Sci. 2012;4:212–7.Google Scholar
- 14.Shivraj N, Chandrashekar M. Pharmacodynamic and pharmacokinetic drug interaction of glimepiride and irbesartan in animal models. Int J Phytopharmacol. 2013;4(3):174–8.Google Scholar